Pitts: EpiPen Controversy Is an Opportunity for the FDA

The video discusses the issue of price gouging in the pharmaceutical industry, highlighting cases like Martin Shkreli and Mylan. It explains how prices have been significantly increased, affecting patients and insurance companies. The video suggests that the FDA can play a crucial role by introducing competition through generics, which could lower prices. It emphasizes the need for regulatory changes to prioritize first-to-market generics, especially in critical areas like emergency care, to drive positive outcomes.

What is the significance of bringing high-quality generics into the marketplace?

What potential impact could the attention on EpiPen and its pricing have on regulatory priorities?